# Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia

> **NCT03433755** · PHASE3 · TERMINATED · sponsor: **Amgen** · enrollment: 259 (actual)

## Conditions studied

- Primary Hypercholesterolemia
- Mixed Dyslipidemia

## Interventions

- **DRUG:** evolocumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT03433755
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-09
- **Primary completion:** 2020-04-24
- **Final completion:** 2020-05-09
- **Target enrollment:** 259 (ACTUAL)
- **Why stopped:** Prematurely Discontinued Amgen decision
- **Last updated:** 2023-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03433755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03433755, "Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03433755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*